4D Molecular Therapeutics’ (FDMT) Buy Rating Reiterated at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a research report sent to investors on Thursday,Benzinga reports. The brokerage currently has a $26.00 price objective on the stock.

A number of other research analysts have also recently issued reports on FDMT. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 21st. Barclays initiated coverage on 4D Molecular Therapeutics in a report on Wednesday, January 28th. They set an “overweight” rating and a $33.00 price target for the company. Wall Street Zen downgraded 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Finally, Royal Bank Of Canada reissued an “outperform” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 7th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $32.71.

4D Molecular Therapeutics Stock Down 4.1%

Shares of 4D Molecular Therapeutics stock opened at $8.61 on Thursday. 4D Molecular Therapeutics has a 12-month low of $2.23 and a 12-month high of $12.34. The stock has a market capitalization of $439.54 million, a P/E ratio of -3.56 and a beta of 2.99. The company has a 50-day simple moving average of $8.75 and a 200 day simple moving average of $9.12.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings results on Wednesday, March 18th. The company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.96. The firm had revenue of $85.09 million for the quarter, compared to analyst estimates of $30.86 million. 4D Molecular Therapeutics had a negative net margin of 164.43% and a negative return on equity of 31.75%. On average, equities analysts anticipate that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.

Institutional Trading of 4D Molecular Therapeutics

Hedge funds have recently modified their holdings of the stock. XTX Topco Ltd bought a new position in 4D Molecular Therapeutics in the 2nd quarter worth approximately $292,000. BVF Inc. IL boosted its position in 4D Molecular Therapeutics by 1.5% in the 2nd quarter. BVF Inc. IL now owns 4,629,289 shares of the company’s stock valued at $17,175,000 after buying an additional 68,000 shares during the last quarter. Dynamic Technology Lab Private Ltd increased its stake in shares of 4D Molecular Therapeutics by 35.6% in the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 16,369 shares of the company’s stock valued at $61,000 after buying an additional 4,295 shares during the period. Baker BROS. Advisors LP acquired a new stake in shares of 4D Molecular Therapeutics in the 4th quarter valued at $3,568,000. Finally, Landing Point Financial Group LLC bought a new stake in shares of 4D Molecular Therapeutics during the fourth quarter worth $142,000. 99.27% of the stock is owned by institutional investors.

Trending Headlines about 4D Molecular Therapeutics

Here are the key news stories impacting 4D Molecular Therapeutics this week:

• Positive Sentiment: High-profile firms reiterated bullish views and raised targets, supporting upside potential — HC Wainwright reaffirmed a “buy” and set a $36 target (very large implied upside). Read More.
• Positive Sentiment: Royal Bank of Canada raised its price target to $35 and gave an “outperform” rating, signaling strong analyst conviction on mid/long-term value. Read More.
• Positive Sentiment: Chardan Capital reaffirmed a “buy” with a $26 target, adding another supportive research note. Read More.
• Positive Sentiment: Fundamental beat: 4D reported Q4 EPS of $0.43 (well ahead of consensus) and revenue of $85.1M, which typically supports higher valuations and reduces near-term execution risk. Read More.
• Neutral Sentiment: Analyst commentary is mixed across the sector; some aggregation pieces note divergent views on FDMT which can increase intraday volatility without clear directional pressure. Read More.
• Neutral Sentiment: Short-interest reports in the latest feeds show anomalous/zero values (reports indicate increases but list 0 shares/NaN), suggesting the data feed is unreliable — this appears to be noise rather than a clear short-squeeze or large shorting event.
• Negative Sentiment: Cantor Fitzgerald issued a “hold” on FDMT, which can dampen momentum from the bullish notes and makes the street’s view less one-sided. Read More.
• Negative Sentiment: New risk disclosure: a TipRanks piece highlights reimbursement and pricing pressures that could materially affect the commercial outlook for FDMT’s gene therapies — a real demand/price-risk that can weigh on valuation and near-term sentiment. Read More.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.